Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study
Last Updated: Tuesday, February 16, 2021
Using real-world data from the ongoing MOST study of patients with specific risk categories of essential thrombocythemia or myelofibrosis, the authors of this 2020 ASH Annual Meeting abstract report that, despite treatment, low-risk patients had greater patient-reported symptom burden and physician-reported signs/symptoms compared with high-risk (treated or untreated) patients.
Advertisement
News & Literature Highlights
